Please login to the form below

Not currently logged in
Email:
Password:

Breast Cancer Now

This page shows the latest Breast Cancer Now news and features for those working in and with pharma, biotech and healthcare.

NICE backs two advanced breast cancer drugs after price cuts

NICE backs two advanced breast cancer drugs after price cuts

Women in England and Wales with advanced breast cancer can now get access to two CDK 4/6 inhibitor drugs - Pfizer’s Ibrance and Novartis’Kisqali - after pricing negotiations between the ... important breakthroughs for women with advanced breast

Latest news

  • Dismay as NICE turns down first-line use of AZ's Faslodex Dismay as NICE turns down first-line use of AZ's Faslodex

    AstraZeneca's hopes of expanding the use of its breast cancer therapy Faslodex in the UK look rocky after NICE rejected the drug in draft guidance. ... Baroness Delyth Morgan, chief executive at medical charity Breast Cancer Now, said the verdict was

  • Novartis claims EU approval for breast cancer drug Kisqali Novartis claims EU approval for breast cancer drug Kisqali

    Novartis claims EU approval for breast cancer drug Kisqali. Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe. ... Novartis can now challenge Pfizer's blockbuster breast cancer drug Ibrance in Europe after gaining approval for its

  • Clovis rockets on maintenance data in ovarian cancer Clovis rockets on maintenance data in ovarian cancer

    their indications into other indications such as breast cancer. ... Another candidate - AbbVie's veliparib - failed two phase III trials in April (in breast and lung cancer) and now looks unlikely to challenge the leaders.

  • NICE relents on Kadcyla after Roche pricing negotiations NICE relents on Kadcyla after Roche pricing negotiations

    The agreement has been welcomed by charity Breast Cancer Now, which has been pushing hard for a price cut on the drug for years. ... Breast Cancer Now delivered a warning about another Roche HER2 drug - Perjeta (pertuzumab) - which it said was at risk

  • AZ's Lynparza shows PARP inhibitor potential in breast cancer AZ's Lynparza shows PARP inhibitor potential in breast cancer

    AstraZeneca's Lynparza was the first PARP inhibitor to reach the market for BRAC-positive ovarian cancer, and is now the first drug in its class to show effectiveness in breast ... The data were well-received at ASCO, with the organisation's president -

More from news
Approximately 2 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    Two days after the student midwife’s tweet, UK organisation Breast Cancer Now shared its own response to the guidance, also tweeting to Pfizer and NICE and urging them to work ... Breast Cancer Now is followed by almost 40, 000, and its tweet, which it

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics